creators_name: Praveen R, Int J Cur Bio Med Sci. creators_id: drpraveen28@gmail.com type: journalp datestamp: 2011-05-02 15:52:37 lastmod: 2011-05-02 15:52:37 metadata_visibility: show title: Tamsulosin � turn a round ispublished: pub subjects: JOURNALS full_text_status: public keywords: Tamsulosin, Alpha, Adrenoceptor abstract: Tamsulosin is a sulfamoylphen-ethylamine derivative, a potent and a selective antagonist of Alpha-1A adrenoceptor. It�s approved in the treatment of LUTS in BPH disease, being a specific Alpha -1A blocker it does not interfere much with the cardiovascular system. Though an age old molecule but still it�s a friendly drug to most of the physicians. Even the recent studies found its as efficacious to some of the newer molecules in the group. date: 2011-04-30 date_type: published publication: Int J Cur Bio Med Sci. volume: 1 number: 2 publisher: CurrentSciDirect Publications pagerange: 39-40 refereed: TRUE referencetext: [1] Hieble JP, Bylund DB, Clarke DE. International union of pharmacology X. Recommendation for nomenclature of alpha-adrenoceptors: consensus update. J Pharmacol Rev 1994;47:267-270. [2] Roosen A, James B, Wood D, Fry C. Clinical and experimental aspects of Adreno-muscarinic synergy in the bladder base and prostate.2009;28(8):938-943. [3] Price DT, Schwinn DA, Lomasney JW. Identification, quantification, and localization of mRNA for three distinct alpha-1 adrenergic receptor subtypes in human prostate.J Urol 1993;150:546-551 [4] Holtgrewe HL. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 1998;51:1-7. [5] Andersson KE. Mode of action of alpha-adrenoreceptor antagonists in the treatment of lower urinary tract symptoms. BJU 2000;85:12-18. [6] Puppo P. Do we know everything about alpha-blockade in the management of lower urinary tract symptoms?.J Eur Urol 2001;39:38-41. [7] Schwinn DA, Michelotti GA. alpha-Adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha subtype in filling symptoms and effects of ageing on vascular expression. BJU 2000;85:6-11. [8] Khoury S, Cockett A, Aso Y. International consultation on urological diseases: a decade of progress. J Prostate 2000;45:194-199 [9] Puppo P. Do we know everything about alpha-blockade in the management of lower urinary tract symptoms?. Eur Urol 2001 Jan; 39 Suppl. 2.: 38-41 [10] Beduschi MC, Beduschi R, Oesterling JE. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist. Urology 1998; 51: 861-72 [11] de Mey C, Michel MC, McEwen J, et al. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998; 33: 481-8 [12] van Hoogdalem EJ, Soeishi Y, Matsushima H, et al. Disposition of the selective [alpha]1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling. J Pharm Sci 1997; 86: 1156-61 [13] Boehringer Ingelheim Pharmaceuticals Incorporated. Flomax (tamsulosin) prescribing information. 2000. [14] Salinas F, Gabriela, Rosette J, Michel, Martin C. Pharmacokinetics and Pharmacodynamics of Tamsulosin in its Modified-Release and Oral Controlled Absorption System Formulations. 2010;49(3):177-88. [15] Kawachi Y, Sakurai T, Sugimura S, Iwata S, Noto K, Honda S et al. Long-term treatment and prognostic factors of α1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: A pilot study comparing naftopidil and tamsulosin hydrochloride.2010;44:38-45. [16] Yamanouchi Pharmaceutical Co. Ltd. Harnal (tamsulosin) prescribing information. 2000 citation: Praveen R, Int J Cur Bio Med Sci. (2011) Tamsulosin � turn a round. [Journal (Paginated)] document_url: http://cogprints.org/7319/1/Tamsulosin_%EF%BF%BD_turn_a_round.pdf